Wire · opportunities
Bayer's SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 November 2026 · Fusion42 review
The U.S. FDA approved Bayer's SUNHARBO (asundexian) 50 mg tablets as the first Factor XIa inhibitor to reduce the risk of secondary stroke in adults with recent non-cardioembolic ischemic stroke or high-risk transient ischemic attack, in combination with antiplatelet therapy. Clinical trial data showed a 26% reduction in ischemic stroke risk compared to placebo, with a similar rate of major bleeding.
This Wire brief sits within Fusion42's coverage of Medtech, and 15 sources have reported it between 9 Nov 2026 and 19 Nov 2026.
◆ ◆ The Wire takeaway
You can now offer a first-in-class stroke prevention treatment that lowers recurrent stroke risk without increasing major bleeding. Neurology and cardiology founders should explore partnerships or integration around this novel Factor XIa inhibitor to address an unmet need in secondary stroke care.
◆ Coverage
15 sources · first reported 9 Nov 2026 · latest 19 Nov 2026
◆ Related on Wire
◆ Topics